v-natal ®: Trisomy 21, 18, 13 and gonosomal aneuploidies

The present blood sample will be screened for the presence of fetal trisomy 21, 18 and 13 (Illumina, verifi technology) after extraction of cell-free DNA and generation of a genomic library using Next-Generation sequencing (NGS). The condition for reimbursement by obligatory health insurance (OHI) is that a first trimester test (measurement of the nuchal translucency in the ultrasound, determination of free beta-hCG and PAPP-A in the blood of the pregnant woman) is carried out beforehand and that it has been shown that the risk of trisomies 21, 18 or 13 is greater than 1:1000. No cost reimbursement for twins. Upon request of the pregnant woman the test can also be carried out from WOP 9+1 as a self-payment service. Communication of the gender only takes place after WOP 12. | Declaration of consent for genetic examination in accordance with GUMG required (see OF Human genetics or www.viollier.ch/en/SGMG_consent)